G. Dock, The influence of complicating diseases upon leukemia, Am J Med Sci, vol.127, pp.563-92, 1904.

E. Kelly and S. J. Russell, History of oncolytic viruses: genesis to genetic engineering, Mol Ther, vol.15, pp.651-660

J. G. Sinkovics and J. C. Horvath, Natural and genetically engineered viral agents for oncolysis and gene therapy of human cancers, Arch Immunol Ther Exp, 2008.

T. Asada, Treatment of human cancer with mumps virus, Cancer, vol.34, pp.1907-1935, 1974.

C. J. Breitbach, J. M. Paterson, and C. G. Lemay, Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow, Mol Ther, vol.15, pp.1686-93, 2007.

M. M. Stanford, C. J. Breitbach, J. C. Bell, and G. Mcfadden, Innate immunity, tumor microenvironment and oncolytic virus therapy: friends or foes?, Curr Opin Mol Ther, vol.10, pp.32-39, 2008.

R. Alemany, Cancer selective adenoviruses, Mol Aspects Med, vol.28, pp.42-58, 2007.

D. F. Stojdl, B. Lichty, and S. Knowles, Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus, Nat Med, vol.6, pp.821-826, 2000.

D. F. Stojdl, B. D. Lichty, and B. R. Tenoever, VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents, Cancer Cell, vol.4, pp.263-75, 2003.

E. D. Whitman, K. Tsung, J. Paxson, and J. A. Norton, In vitro and in vivo kinetics of recombinant vaccinia virus cancer-gene therapy, Surgery, vol.116, pp.183-191, 1994.

M. F. Gnant, M. Puhlmann, H. R. Alexander, J. Bartlett, and D. L. , Systemic administration of a recombinant vaccinia virus expressing the cytosine deaminase gene and subsequent treatment with 5-fluorocytosine leads to tumor-specific gene expression and prolongation of survival in mice, Cancer Res, vol.59, pp.3396-403, 1999.

J. Brun, D. Mcmanus, and C. Lefebvre, Identification of genetically modified Maraba virus as an oncolytic rhabdovirus, Mol Ther, vol.18, pp.40-49, 2010.

S. H. Thorne, T. H. Hwang, and W. E. O'gorman, Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963, J Clin Invest, vol.117, pp.3350-3358, 2007.

S. Naik, R. Nace, G. N. Barber, and S. J. Russell, Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferonbeta, Cancer Gene Ther, vol.19, pp.443-50, 2012.

D. Zamarin, L. Martinez-sobrido, and K. Kelly, Enhancement of oncolytic properties of recombinant newcastle disease virus through antagonism of cellular innate immune responses, Mol Ther, vol.17, pp.697-706, 2009.

D. H. Kirn, Y. Wang, and W. Liang, Enhancing poxvirus oncolytic effects through increased spread and immune evasion, Cancer Res, vol.68, pp.2071-2076, 2008.

J. Jin, H. Liu, and C. Yang, Effective gene-viral therapy of leukemia by a new fiber chimeric oncolytic adenovirus expressing TRAIL: in vitro and in vivo evaluation, Mol Cancer Ther, vol.8, pp.1387-97, 2009.

G. Ungerechts, C. Springfeld, and M. E. Frenzke, Lymphoma chemovirotherapy: CD20-targeted and convertase-armed measles virus can synergize with fludarabine, Cancer Res, vol.67, pp.10939-10986, 2007.

D. Dingli, K. W. Peng, and M. E. Harvey, Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter, Blood, vol.103, pp.1641-1647, 2004.

C. Liu, S. J. Russell, and K. W. Peng, Systemic therapy of disseminated myeloma in passively immunized mice using measles virus-infected cell carriers, Mol Ther, vol.18, pp.1155-64, 2010.

J. Pol, J. Rességuier, and B. Lichty, Oncolytic viruses: a step into cancer immunotherapy, Virus Adaptation and Treatment, vol.4, pp.1-21, 2012.

J. H. Lee, M. S. Roh, and Y. K. Lee, Oncolytic and immunostimulatory efficacy of a targeted oncolytic poxvirus expressing human GM-CSF following intravenous administration in a rabbit tumor model, Cancer Gene Ther, vol.17, pp.73-82, 2009.

N. Lei, F. B. Shen, and J. H. Chang, An oncolytic adenovirus expressing granulocyte macrophage colony-stimulating factor shows improved specificity and efficacy for treating human solid tumors, Cancer Gene Ther, vol.16, pp.33-43, 2009.

B. Kaur, T. P. Cripe, and E. A. Chiocca, Buy one get one free": armed viruses for the treatment of cancer cells and their microenvironment, Curr Gene Ther, vol.9, pp.341-55, 2009.

T. L. Nguyen, M. G. Wilson, and J. Hiscott, Oncolytic viruses and histone deacetylase inhibitors-a multi-pronged strategy to target tumor cells, Cytokine Growth Factor Rev, vol.21, pp.153-162, 2010.

K. Ikeda, T. Ichikawa, and H. Wakimoto, Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses, Nat Med, vol.5, pp.881-888, 1999.

J. S. Diallo, L. Boeuf, F. Lai, and F. , A high-throughput pharmacoviral approach identifies novel oncolytic virus sensitizers, Mol Ther, vol.18, pp.1123-1132, 2010.

B. J. Passer, T. Cheema, and B. Zhou, Identification of the ENT1 antagonists dipyridamole and dilazep as amplifiers of oncolytic herpes simplex virus-1 replication, Cancer Res, vol.70, pp.3890-3895, 2010.

S. J. Russell, K. W. Peng, and J. C. Bell, Oncolytic virotherapy, Nat Biotechnol, vol.30, pp.658-70, 2012.

C. J. Breitbach, J. Burke, and D. Jonker, Intravenous delivery of a multimechanistic cancer-targeted oncolytic poxvirus in humans, Nature, vol.477, pp.99-102, 2011.

Y. Touchefeu, U. Schick, and K. J. Harrington, Le virus de la rougeole -Un futur traitement en cancérologie ?, Med Sci, vol.28, pp.388-94, 2012.

G. Lemay, Apprivoiser nos ennemis pour en faire des alliés : la « virothérapie » anticancéreuse, Med Sci, vol.28, pp.339-379, 2012.

V. Janelle, L. Poliquin, and A. Lamarre, Le virus de la stomatite vésiculaire dans la lutte contre le cancer, Med Sci, vol.29, pp.175-82, 2013.

W. R. Jarnagin, J. S. Zager, and D. Klimstra, Neoadjuvant treatment of hepatic malignancy: an oncolytic herpes simplex virus expressing IL-12 effectively treats the parent tumor and protects against recurrence-after resection, Cancer Gene Ther, vol.10, pp.215-238, 2003.

R. J. Wong, M. K. Chan, and Z. Yu, Effective intravenous therapy of murine pulmonary metastases with an oncolytic herpes virus expressing interleukin 12, Clin Cancer Res, vol.10, pp.251-260, 2004.

S. Varghese, S. D. Rabkin, and R. Liu, Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers, Cancer Gene Ther, vol.13, pp.253-65, 2006.

J. N. Parker, G. Y. Gillespie, and C. E. Love, Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors, Proc Natl Acad Sci, vol.97, pp.2208-2221, 2000.

J. H. Huang, S. N. Zhang, and K. J. Choi, Therapeutic and tumor-specific immunity induced by combination of dendritic cells and oncolytic adenovirus expressing IL-12 and 4-1BBL, Mol Ther, vol.18, pp.264-74, 2010.

H. Fukuhara, Y. Ino, and T. Kuroda, Triple gene-deleted oncolytic herpes simplex virus vector double-armed with interleukin 18 and soluble B7-1 constructed by bacterial artificial chromosome-mediated system, Cancer Res, vol.65, pp.10663-10671, 2005.

B. W. Bridle, K. B. Stephenson, and J. E. Boudreau, Potentiating cancer immunotherapy using an oncolytic virus, Mol Ther, vol.184, pp.4269-75, 2010.

P. Castelo-branco, B. J. Passer, and J. S. Buhrman, Oncolytic herpes simplex virus armed with xenogeneic homologue of prostatic acid phosphatase enhances antitumor efficacy in prostate cancer, Gene Ther, vol.17, pp.805-815, 2010.

K. Ottolino-perry, J. S. Diallo, and B. D. Lichty, Intelligent design: combination therapy with oncolytic viruses, Mol Ther, vol.18, pp.251-63, 2010.

L. Boeuf, F. Diallo, J. S. Mccart, and J. A. , Synergistic interaction between oncolytic viruses augments tumor killing, Mol Ther, vol.18, pp.888-95, 2010.